Results 111 to 120 of about 2,874 (169)

Staphylococcus aureus Augments Epithelial Skin Barrier Damage Through T Cell Activation in Cutaneous T Cell Lymphoma

Allergy, EarlyView.
Staphylococcus aureus, commonly colonising CTCL patients, augments skin barrier dysfunction. Staphylococcal enterotoxins induce T‐cell release of barrier‐repressing cytokines (IL‐4, IL‐13, IL‐22, OSM). Cytokine signalling drives JAK‐dependent downregulation of filaggrin and loricrin in keratinocytes. Antibiotic‐mediated eradication of S. aureus induces
Maria Gluud, Emil M. Pallesen, Ziao Zeng, Martin R. J. Namini, Chella Krishna Vadivel, Lise Mette Rahbek Gjerdrum, Lang Yan, Sana Ahmad, Lise M. Lindahl, Michael Bzorek, Maria R. Kamstrup, Saptaswa Dey, Sisse Rye Ostrowski, Erik Sørensen, Pia Rantakari, Charlotte Menne Bonefeld, Carsten Geisler, Anders Woetmann, Riitta Lahesmaa, Lars Iversen, Peter Wolf, Thomas Litman, Terkild B. Buus, Niels Ødum   +23 more
wiley   +1 more source

Mapping Allergen B‐ and T‐Cell Epitopes: Technological Advances and Their Role in Precision Allergy Therapy

Allergy, EarlyView.
ABSTRACT Allergic diseases arise from aberrant immune recognition of otherwise harmless environmental proteins and are driven by epitope‐specific interactions between allergens and the adaptive immune system. Although component‐resolved diagnostics have improved molecular characterisation of sensitization, they remain limited to whole‐allergen ...
Mark Møiniche, Josefine Corneliussen, Kristoffer H. Johansen, Alexandre Ruiz‐Carrasco, Caroline Paulsen, Yuchen Li, Carolina Barra, Sandhya Bangaru, Monica L. Fernández‐Quintero, Ewa Bartko, Lars Blom, Esperanza Rivera‐de‐Torre   +11 more
wiley   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

Transgenic selection and underlying mechanisms in apicomplexan parasites

The FEBS Journal, EarlyView.
Transgenic selection markers have driven genetic engineering in apicomplexans, enabling precise, iterative experiments. This review discusses mechanistic details of drug selection markers, strategies for marker recycling, and practical considerations for several clinically relevant parasites.
Swaroop Peddiraju, Rakhee Lohia, Nishith Gupta   +2 more
wiley   +1 more source

A guide to the ecological limitations of phage therapy of bacterial biofilms: Is what's best for the phage best for the physician?

The FEBS Journal, EarlyView.
Bacteriophages—viruses that kill bacteria—are promising weapons against bacterial biofilms: sessile communities notoriously resistant to antibiotics. Yet phages evolved not so much to eradicate bacteria as to obtain new bacteria to infect. That goal, however, may conflict with the physician's objective of complete bacterial clearance.
Stephen T. Abedon
wiley   +1 more source

Gene Editing for Haemophilia—The Next Frontier

Haemophilia, EarlyView.
ABSTRACT The recently approved haemophilia A and B gene therapies via adeno‐associated virus (AAV) showed a promising therapeutic response after a single injection, but there are still limitations, including the potential loss of transgene expression and restriction in adults.
Mirko Pinotti, Gregory A. Newby, Sundar Selvaraj, Steven W. Pipe   +3 more
wiley   +1 more source

Staphylococcus aureus Sb‐1 Bacteriophage Alters Frequency and Subset Distribution of Human Innate Lymphoid Cells

Allergy, EarlyView.
Ramazan Rozumbetov, Ismail Ogulur, Anja Heider, Anna Globinska, Nina Chanishvili, Elene Kakabadze, Marina Goderdzishvili, Nino Grdzelishvili, Nata Bakuradze, Moelong Yu, Tamara Aripova, Adolat Ismailova, Nikolaos Papadopoulos, Mubeccel Akdis, Cezmi A. Akdis   +14 more
wiley   +1 more source

Synergistic engineering of Casδ nuclease for robust genome editing

Journal of Integrative Plant Biology, EarlyView.
A hierarchical engineering strategy was used to enhance the editing activity of Casδ, yielding an optimized variant termed enCasδ. This variant enables robust genome editing in animal cells and plants, with overall editing performance comparable to that of SpCas9 and other Cas12 nucleases.
Fanghui Ge, Chenchen Peng, Yang Du, Ying Chen, Zilong Zhao, Meixia Yu, Huairu Feng, Yuyang Xie, Siwei Sun, Shengnan Liu, Beibei Xin, Haiming Zhao, Sen Wu, Chao Bian, Zhijia Yang, Jinsheng Lai, Jian Chen   +16 more
wiley   +1 more source